ACRV vs. OGI, IVA, TELO, ATOS, LFCR, IXHL, ZVRA, GALT, GLSI, and TRVI
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Organigram (OGI), Inventiva (IVA), Telomir Pharmaceuticals (TELO), Atossa Therapeutics (ATOS), Lifecore Biomedical (LFCR), Incannex Healthcare (IXHL), Zevra Therapeutics (ZVRA), Galectin Therapeutics (GALT), Greenwich LifeSciences (GLSI), and Trevi Therapeutics (TRVI). These companies are all part of the "pharmaceutical preparations" industry.
Organigram (NASDAQ:OGI) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Acrivon Therapeutics has a consensus price target of $22.88, indicating a potential upside of 157.31%. Given Organigram's higher probable upside, analysts clearly believe Acrivon Therapeutics is more favorable than Organigram.
Organigram received 172 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 96.15% of users gave Acrivon Therapeutics an outperform vote while only 70.61% of users gave Organigram an outperform vote.
In the previous week, Acrivon Therapeutics had 1 more articles in the media than Organigram. MarketBeat recorded 16 mentions for Acrivon Therapeutics and 15 mentions for Organigram. Organigram's average media sentiment score of 0.71 beat Acrivon Therapeutics' score of 0.36 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.
Organigram has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500.
Acrivon Therapeutics has a net margin of 0.00% compared to Acrivon Therapeutics' net margin of -188.38%. Acrivon Therapeutics' return on equity of -40.19% beat Organigram's return on equity.
34.6% of Organigram shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 0.1% of Organigram shares are held by insiders. Comparatively, 7.3% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Acrivon Therapeutics has lower revenue, but higher earnings than Organigram. Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Organigram, indicating that it is currently the more affordable of the two stocks.
Summary
Acrivon Therapeutics beats Organigram on 10 of the 17 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
